Niagen Bioscience Inc (NASDAQ: NAGE) is a Healthcare company (Biotechnology) with a market capitalization of $162M. The Maz Rating grades it against the other companies in its sector.
Niagen Bioscience Inc's current Maz Rating and its five factor grades are for members: log in to see them.
At $2.04, Niagen Bioscience Inc trades at 16.0x trailing earnings, 1.3x sales and 1.9x book value, with an EV/EBITDA of 13.6. Over the last twelve months it generated about $123M of revenue and $10M of net income. It runs a gross margin of 63.9%, an operating margin of 2.3% and a net margin of 8.4%. It shows return on equity of 12.6%, return on invested capital of 2.8% and a free cash flow yield of 2.8%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 5.93. Over the past 52 weeks the share price ranged from $1.95 to $7.12, with a beta of 2.09.
Niagen Bioscience Inc does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 6 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Niagen Bioscience Inc (NAGE) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 0.00% / 30% · Interest income / Revenue 1.52% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 0.00% / 33% · Receivables / Mkt Cap (36m) 3.13% / 49% · Interest income / Revenue 1.52% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 0.00% / 33.33% · Receivables / Mkt Cap (24m) 3.13% / 33.33% · Interest income / Revenue 1.52% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.47% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 45.4% / 33.33% · Receivables / Avg Assets (4Q) 8.77% / 33.33% · Interest income / Revenue 1.52% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 0.00% / 33.33% · (Cash+Recv) / Total Assets 6.29% / 33.33% · Interest income / Revenue 1.52% / 5% | Pass |
It depends on the standard you follow. As of September 2026, Niagen Bioscience Inc (NAGE) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and FTSE, and fails MSCI.
Yes. Niagen Bioscience Inc is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.52% of each dividend: Niagen Bioscience Inc's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.